Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG versus MERILOG SOLOSTAR.
ADMELOG vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating downstream signaling pathways to facilitate cellular glucose uptake, inhibit hepatic gluconeogenesis, and promote glycogen synthesis, lipogenesis, and protein synthesis.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 2-4 doses. Typical starting dose: 0.4-0.6 units/kg/day. Administer within 15 minutes before or immediately after a meal.
0.5 mg subcutaneously once a day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours (subcutaneous administration). This short half-life reflects rapid absorption and clearance, suitable for prandial glucose control.
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Renal (primarily as unchanged drug, following degradation by insulin-degrading enzyme). Approximately 60-80% of a dose is excreted renally; the remainder is metabolized in the liver and kidneys.
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category C
Category C
Insulin
Insulin